SI3191487T1 - Spirociklični inhibitorji katepsina C - Google Patents

Spirociklični inhibitorji katepsina C

Info

Publication number
SI3191487T1
SI3191487T1 SI201530977T SI201530977T SI3191487T1 SI 3191487 T1 SI3191487 T1 SI 3191487T1 SI 201530977 T SI201530977 T SI 201530977T SI 201530977 T SI201530977 T SI 201530977T SI 3191487 T1 SI3191487 T1 SI 3191487T1
Authority
SI
Slovenia
Prior art keywords
cathepsin
spirocyclic
inhibitors
spirocyclic inhibitors
Prior art date
Application number
SI201530977T
Other languages
English (en)
Slovenian (sl)
Inventor
Viktor Vintonyak
Matthias Grauert
Marc Grundl
Alexander Pautsch
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of SI3191487T1 publication Critical patent/SI3191487T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201530977T 2014-09-12 2015-09-08 Spirociklični inhibitorji katepsina C SI3191487T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14184613 2014-09-12
EP15757523.4A EP3191487B1 (en) 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c
PCT/EP2015/070449 WO2016038007A1 (en) 2014-09-12 2015-09-08 Spirocyclic inhibitors of cathepsin c

Publications (1)

Publication Number Publication Date
SI3191487T1 true SI3191487T1 (sl) 2019-12-31

Family

ID=51535355

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530977T SI3191487T1 (sl) 2014-09-12 2015-09-08 Spirociklični inhibitorji katepsina C

Country Status (34)

Country Link
US (3) US9540373B2 (en:Method)
EP (2) EP3511331A1 (en:Method)
JP (2) JP2017526716A (en:Method)
KR (1) KR102510588B1 (en:Method)
CN (2) CN107074870B (en:Method)
AP (1) AP2017009733A0 (en:Method)
AU (1) AU2015314355B2 (en:Method)
BR (1) BR112017003433B1 (en:Method)
CA (1) CA2960916C (en:Method)
CL (1) CL2017000432A1 (en:Method)
CO (1) CO2017002268A2 (en:Method)
CY (1) CY1123033T1 (en:Method)
DK (1) DK3191487T3 (en:Method)
EA (1) EA031376B1 (en:Method)
ES (1) ES2749009T3 (en:Method)
HK (1) HK1255362A1 (en:Method)
HR (1) HRP20191756T1 (en:Method)
HU (1) HUE047208T2 (en:Method)
IL (1) IL250262B (en:Method)
LT (1) LT3191487T (en:Method)
MX (2) MX378099B (en:Method)
MY (1) MY188382A (en:Method)
NZ (1) NZ728684A (en:Method)
PE (1) PE20170438A1 (en:Method)
PH (1) PH12017500453B1 (en:Method)
PL (1) PL3191487T3 (en:Method)
PT (1) PT3191487T (en:Method)
RS (1) RS59444B1 (en:Method)
SA (1) SA517381064B1 (en:Method)
SG (1) SG11201701633SA (en:Method)
SI (1) SI3191487T1 (en:Method)
TW (1) TWI687424B (en:Method)
UA (1) UA118610C2 (en:Method)
WO (1) WO2016038007A1 (en:Method)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
NO2699580T3 (en:Method) 2014-01-24 2018-02-24
JP6529575B2 (ja) * 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
JP2017526716A (ja) * 2014-09-12 2017-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃのスピロ環状阻害剤
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018162312A1 (en) * 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
KR20200118103A (ko) * 2018-02-07 2020-10-14 인스메드 인코포레이티드 Anca 관련 혈관염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
FI3758708T3 (fi) 2018-03-01 2025-02-18 Astrazeneca Ab (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN110256429B (zh) * 2019-06-17 2021-06-22 广东药科大学 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用
CN110257504A (zh) * 2019-06-30 2019-09-20 中南大学 一种难治性哮喘检测标记物的筛选方法及其应用
WO2022020245A1 (en) 2020-07-20 2022-01-27 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
US20240002386A1 (en) * 2020-11-17 2024-01-04 Vertex Pharmaceuticals Incorporated Solid forms of 4-(5-(4-fluorophenyl)-6-(tetrahydro-2h-pyran-4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid
CN116157405A (zh) * 2020-12-04 2023-05-23 瑞石生物医药有限公司 组织蛋白酶c小分子抑制剂及其医药用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
CN119317620A (zh) 2022-06-13 2025-01-14 亚力维克希斯股份有限公司 氮杂环烷基羰基环状胺化合物
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途
WO2025214464A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Crystalline forms of (s) -n- (1-cyano-2- (2-fluoro-4- (1' - (oxetan-3-yl) -3h-spiro [isobenzofuran-1, 4' -piperidin] -6-yl) phenyl) ethyl) -2-azabicyclo [2.2.2] octane-1-carboxamide

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125727A (en) 1976-10-18 1978-11-14 American Cyanamid Company Method of preparing imidazoisoindolediones
GB8922355D0 (en) 1989-10-04 1989-11-22 British Telecomm Sealing gland
GEP20012487B (en) 1998-09-16 2001-07-25 Merab Lomia Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
ATE409482T1 (de) 2001-03-02 2008-10-15 Merck Frosst Canada Ltd Cathepsincystein-proteasehemmer
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US20070099958A1 (en) 2003-06-18 2007-05-03 Prozymex A/S Protease inhibitors
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
US20060223846A1 (en) 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
MX2008014800A (es) * 2006-06-01 2008-12-02 Sanofi Aventis Nitrilos espirociclicos como inhibidores de proteasa.
WO2008047544A1 (en) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2009047829A1 (ja) 2007-10-12 2009-04-16 Fujitsu Limited Ｉｐ電話自動試験システム及び方法
MX2010006110A (es) 2007-12-12 2010-06-25 Astrazeneca Ab Peptidil-nitrilos y usos de los mismos como inhibidores de la dipeptidil-peptidasa i.
KR20120034639A (ko) 2009-05-07 2012-04-12 아스트라제네카 아베 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
MX2014012989A (es) 2012-04-27 2015-01-22 Glaxo Group Ltd Compuestos novedosos.
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
AR091112A1 (es) 2012-05-22 2015-01-14 Genentech Inc Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
NZ706857A (en) 2012-09-28 2018-05-25 Ignyta Inc Azaquinazoline inhibitors of atypical protein kinase c
EP2908806A1 (en) * 2012-10-09 2015-08-26 Boehringer Ingelheim International GmbH Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
KR102057366B1 (ko) 2012-10-15 2019-12-18 에피자임, 인코포레이티드 치환된 벤젠 화합물
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
UA117572C2 (uk) 2012-11-01 2018-08-27 Інсайт Холдинґс Корпорейшн Трициклічні конденсовані похідні тіофену як інгібітори jak
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
SG11201504946VA (en) 2012-12-21 2015-07-30 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
SMT201800230T1 (it) 2012-12-21 2018-07-17 Plexxikon Inc Composti e metodi per la modulazione della chinasi e loro indicazioni
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9617272B2 (en) 2013-03-14 2017-04-11 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
MX355945B (es) 2013-03-14 2018-05-07 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
PL2970283T3 (pl) * 2013-03-14 2021-05-31 Boehringer Ingelheim International Gmbh Podstawione (benzylocyjanometylo)amidy kwasu 2-aza-bicyklo[2.2.1]heptano-3-karboksylowego będące inhibitorami katepsyny c
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
US8877775B2 (en) * 2013-03-14 2014-11-04 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
ES2675876T3 (es) * 2014-04-29 2018-07-13 Carebay Europe Ltd Dispositivo para ajustar la profundidad de inserción de aguja
WO2016003723A1 (en) 2014-07-03 2016-01-07 Bridgestone Americas Tire Operations, Llc Sidewall decoration on rim guard
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
AR101696A1 (es) 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
US10059699B2 (en) 2014-09-12 2018-08-28 Glaxosmithkline Intellectual Property (No.2) Limited Tetrahydroquinoline derivatives as bromodomain inhibitors
JP2017526716A (ja) * 2014-09-12 2017-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃのスピロ環状阻害剤

Also Published As

Publication number Publication date
EA201790576A1 (ru) 2017-08-31
NZ728684A (en) 2022-09-30
SA517381064B1 (ar) 2021-02-07
PE20170438A1 (es) 2017-04-28
MX2019009695A (es) 2019-10-07
JP2017526716A (ja) 2017-09-14
LT3191487T (lt) 2019-10-10
MX2017003156A (es) 2017-05-23
TWI687424B (zh) 2020-03-11
RS59444B1 (sr) 2019-11-29
EP3511331A1 (en) 2019-07-17
CN107074870B (zh) 2019-07-12
PH12017500453A1 (en) 2017-07-31
MX367316B (es) 2019-08-15
MY188382A (en) 2021-12-07
TW201625647A (zh) 2016-07-16
CA2960916A1 (en) 2016-03-17
UA118610C2 (uk) 2019-02-11
PL3191487T3 (pl) 2020-03-31
US20160075704A1 (en) 2016-03-17
USRE47636E1 (en) 2019-10-08
US9540373B2 (en) 2017-01-10
CO2017002268A2 (es) 2017-06-20
CA2960916C (en) 2023-03-07
US20170073352A1 (en) 2017-03-16
CL2017000432A1 (es) 2017-10-20
AU2015314355B2 (en) 2019-06-20
BR112017003433A2 (pt) 2017-11-28
HK1255362A1 (zh) 2019-08-16
EA031376B1 (ru) 2018-12-28
WO2016038007A1 (en) 2016-03-17
AP2017009733A0 (en) 2017-02-28
JP2018044011A (ja) 2018-03-22
EP3191487A1 (en) 2017-07-19
DK3191487T3 (da) 2019-10-28
CN108047240A (zh) 2018-05-18
MX378099B (es) 2025-03-10
JP6360961B2 (ja) 2018-07-18
KR102510588B1 (ko) 2023-03-17
KR20170054489A (ko) 2017-05-17
AU2015314355A1 (en) 2017-02-16
IL250262B (en) 2020-03-31
PT3191487T (pt) 2019-11-18
SG11201701633SA (en) 2017-03-30
IL250262A0 (en) 2017-03-30
PH12017500453B1 (en) 2021-08-06
EP3191487B1 (en) 2019-08-07
HUE047208T2 (hu) 2020-04-28
US9879026B2 (en) 2018-01-30
CN108047240B (zh) 2020-08-04
CN107074870A (zh) 2017-08-18
ES2749009T3 (es) 2020-03-18
HRP20191756T1 (hr) 2019-12-27
CY1123033T1 (el) 2021-10-29
BR112017003433B1 (pt) 2023-11-14

Similar Documents

Publication Publication Date Title
IL250262B (en) Spirocyclic cathepsin c inhibitors
IL272130B (en) Inhibitors of specific lysine demethylase-1
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
PH12016501922A1 (en) Substituted spirocyclic inhibitors of autotaxin
ZA201700304B (en) Spirocycloheptanes as inhibitors of rock
IL250876A0 (en) Inhibitors of specific lysine demethylase-1
IL248505B (en) Inhibitors of specific lysine demethylase-1
IL249733A0 (en) Inhibitors of specific lysine demethylase-1
ZA201700072B (en) Inhibitors of lysine specific demethylase-1
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases